AbCellera Biologics Inc.
11.05USD
-0.3900 (-3.41%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 485.4M | 38.0M | 28.8M | 75.1M | 25.2M | 26.2M |
| Q1 | 316.6M | 12.2M | 10.0M | 4.2M | 8.3M | — |
| Q2 | 45.9M | 10.1M | 7.3M | 17.1M | 4.1M | — |
| Q3 | 101.4M | 6.6M | 6.5M | 9.0M | 5.3M | — |
| Q4 | 21.5M* | 9.2M* | 5.1M* | 44.9M* | 6.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .500 | -.510 | -.550 | -.490 | -.656 | -.715 |
| Q1 | .540 | -.140 | -.140 | -.150 | -.140 | — |
| Q2 | -.020 | -.110 | -.130 | -.120 | -.180 | — |
| Q3 | .080 | -.100 | -.170 | -.190 | -.173 | — |
| Q4 | -.095* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.163* |
| -.116* |
| -.030* |
| -.170 |
| — |